0812 GMT - Smith & Nephew's results topped expectations, with reassuring strength in particular at its U.S. orthopedics business, which will be welcomed by investors, RBC Capital Markets analysts say in a note. The U.K. medical-technology company's 4Q orthopedics underlying growth of 6% was ahead of RBC's expectations of 4.9%, driven by strength in its hips and knees business in the U.S., the analysts say. The company posted a 2025 outlook in line with consensus and expects China headwinds to clear through 1Q, in line with previous commentary, they say. Shares are up 9.7% at 1,144.50 pence. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 25, 2025 03:12 ET (08:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.